A Placebo- and Active-Controlled Assessment of 6- and 50-mg Oral Doxepin on Cardiac Repolarization in Healthy Volunteers: A Thorough QT Evaluation
- 31 July 2011
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 33 (7), 851-862
- https://doi.org/10.1016/j.clinthera.2011.05.092
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary InsomniaSleep, 2010
- Efficacy and safety of doxepin 6 mg in a model of transient insomniaSleep Medicine, 2010
- Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Adults with Primary InsomniaSleep, 2007
- Psychotropic drugs and the ECG: focus on the QTc intervalExpert Opinion on Pharmacotherapy, 2002
- Pharmacological profile of antidepressants and related compounds at human monoamine transportersEuropean Journal of Pharmacology, 1997
- Electrocardiographic Effects of Fluoxetine and Doxepin in Patients With Major Depressive DisorderJournal of Clinical Psychopharmacology, 1997
- Binding of antidepressants to human brain receptors: focus on newer generation compoundsPsychopharmacology, 1994
- Cardiovascular effects of doxepin in cardiac patients with ventricular arrhythmiasClinical Pharmacology & Therapeutics, 1987
- Cardiovascular Effects of Tricyclic Antidepressants in Depressed Patients with Chronic Heart DiseaseNew England Journal of Medicine, 1982
- Doxepin Up-to-DateDrugs, 1977